SEARCH:   Advanced

Blood, 15 April 2006, Vol. 107, No. 8, pp. 3058-3064. Prepublished online as a Blood First Edition Paper on December 29, 2005; DOI 10.1182/blood-2005-04-1570. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-04-1570v1 107/8/3058    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Glass, B. Articles by Schmitz, N. Search for Related Content PubMed PubMed Citation Articles by Glass, B. Articles by Schmitz, N. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma Bertram Glass, Marita Kloess, Martin Bentz, Günter Schlimok, Wolfgang E. Berdel, Alfred Feller, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Norbert Schmitz, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) From the Department of Hematology and Oncology, University Hospital Göttingen; Institute of Medical Informatics, Statistics, and Epidemiology, University of Leipzig; Department of Hematology and Oncology, Community Hospital Karlsruhe; Department of Internal Medicine II, Klinikum Augsburg; Department of Internal Medicine A, University of Münster; Institute of Pathology, University of Schleswig-Holstein, Lübeck; Saarland University Medical School, Hospital of Medicine, Homburg/Saar; and Department of Hematology, Asklepios Klinik (AK) St. Georg, Hamburg, Germany. Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal. At dose level 1 (DL1), course 1 consisted of cyclophosphamide 1500 mg/m2, doxorubicin (Adriamycin) 70 mg/m2, vincristine 2 mg, etoposide 450 mg/m2, and prednisone 500 mg. With courses 2 and 3 cyclophosphamide and etoposide were escalated to 4500 mg/m2 and 600 mg/m2, respectively. With course 4 cyclophosphamide and etoposide were given at 6000 mg/m2 and 1000 mg/m2, respectively. At DL2 etoposide was further increased to 600, 960, 960, and 1480 mg/m2 with courses 1 to 4, respectively. Therapy as per protocol was completed by 81.8% of patients. Overall survival at 5 years was 67.2%, freedom from treatment failure (FFTF) was 62.1%, and treatment-related mortality was 4.5%. There was a trend to better FFTF at DL2 compared to DL1 (66.9% versus 54.2%). Repetitive HDT with escalated CHOP plus etoposide is feasible and effective treatment of patients with aNHL. DL2 of this therapy is being used in an ongoing phase 3 study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling Clin. Cancer Res., December 1, 2007; 13(23): 7073 - 7079. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020